Paracetamol IV market projected to reach USD 1.3 billion by 2034 with 4.2% CAGR

From GlobeNewswire: 2025-01-20 06:40:00

The Paracetamol IV market was valued at USD 860.7 million in 2024, with a projected CAGR of 4.2% from 2025 to 2034. It is widely used for its analgesic and antipyretic properties, especially in post-surgical recovery and severe infections. The demand for non-opioid pain relief in hospitals is driving market growth.

Paracetamol IV is crucial for managing moderate to severe pain in hospital settings where oral medication is not suitable. It is commonly used in surgical settings to reduce the need for opioid-based analgesics. The market is divided into surgical and non-surgical applications, with the surgical segment leading in 2024.

With a focus on pain management and fever reduction, Paracetamol IV is a key component of multimodal analgesia protocols. Hospitals and clinics are the dominant end-users, benefiting from its rapid action and controlled dosage. The U.S. held a significant share of the North America market in 2024, driven by the rise in surgeries and the adoption of non-opioid pain relief.

Major players in the Paracetamol IV market include AdvaCare Pharma, Pfizer, and Cipla Inc. Industry insights cover key trends, growth drivers, challenges, and regulatory landscapes. Global Market Insights offers comprehensive reports for industries such as technology, renewable energy, and biotechnology to aid strategic decision-making.



Read more at GlobeNewswire: Paracetamol IV Market to hit USD 1.3 billion by 2034, says